Allan Reine
2021 - Foghorn Therapeutics
In 2021, Allan Reine earned a total compensation of $2M as Chief Financial Officer at Foghorn Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $249,600 |
|---|---|
| Option Awards | $1,348,746 |
| Salary | $416,000 |
| Total | $2,014,346 |
Reine received $1.3M in option awards, accounting for 67% of the total pay in 2021.
Reine also received $249.6K in non-equity incentive plan and $416K in salary.
Rankings
In 2021, Allan Reine's compensation ranked 6,027th out of 12,415 executives tracked by ExecPay. In other words, Reine earned more than 51.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,027 out of 12,415 | 52nd |
Division Manufacturing | 2,550 out of 5,501 | 54th |
Major group Chemicals And Allied Products | 1,116 out of 2,371 | 53rd |
Industry group Drugs | 994 out of 2,092 | 53rd |
Industry Pharmaceutical Preparations | 716 out of 1,542 | 54th |
Source: SEC filing on April 29, 2022.
Reine's colleagues
We found three more compensation records of executives who worked with Allan Reine at Foghorn Therapeutics in 2021.